[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hematopoietic-and-lymphatic-system-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hematopoietic-and-lymphatic-system-neoplasm":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,65,0,25,[9,43,65,85,107,128,149,169,191,218,247,293,311,328,345,373,391,412,430,454,475,498,517,536,554],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100603814","telephone-based-coaching-sessions-tac-to-improve-advance-care-planning-participation-in-advanced-cancer-patients-and-their-support-person-100603814",false,"NCT07141407","Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Patients and Their Support Person","Community-Engaged Pilot Testing of Talking About Cancer (TAC) to Improve Engagement in Advance Care Planning","Inclusion Criteria:\n\n* PATIENT: Current diagnosis of stage III or IV cancer\n* PATIENT: Able to provide informed consent\n* PATIENT: Fluent in English or Spanish\n* PATIENT: Have access to a telephone, computer, or mobile device\n* CAREGIVER (SUPPORT PERSON): Person patient indicates provides support\n* CAREGIVER (SUPPORT PERSON): English or Spanish speaking\n* CAREGIVER (SUPPORT PERSON): 18 years of age or older\n* CAREGIVER (SUPPORT PERSON): Able to provide informed consent\n\nExclusion Criteria:\n\n* PATIENT: Too ill or weak to complete the interviews (as judged by the interviewer)\n* PATIENT: Receiving hospice at the time of enrollment\n* PATIENT: Younger than age 18",true,"ALL","18 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","This clinical trial studies whether telephone-based coaching sessions, Talking About Cancer (TAC), work to improve engagement in advance care planning (ACP) in patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and their support person. Participation in ACP, which includes having end of life (EOL) care conversations and completing advance directives (e.g., living will, health care proxy, do not resuscitate order), improves quality EOL care. Despite this, less than half of patients with advanced cancer have EOL care conversations or complete advance directives. TAC coaching sessions are delivered by a social worker over the phone. They are designed to help patients and their support person communicate about ACP, manage the distress these conversations can cause, and participate in the process of ACP with a clear action plan of having goals-of-care conversations and completing advance directives. This may be an effective way to improve ACP participation in advanced cancer patients and their support person.",[28,29],"Advanced Malignant Solid Neoplasm","Hematopoietic and Lymphatic System Neoplasm","RECRUITING","2026-08-20",{"date":33,"type":34},"2026-08-21","ACTUAL",{"date":36,"type":34},"2026-04-08",{"date":38,"type":22},"2026-12-14",{"name":40,"class":41},"Fred Hutchinson Cancer Center","OTHER",3,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":64},"100539463","validation-of-dna-methylation-markers-for-universal-and-site-specific-guided-cancer-detection-vanguard-study-100539463","NCT06304168","Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study","Validation of DNA Methylation Markers for the Universal and Site-Specific Guided Cancer Detection (the VANGUARD Study)","Inclusion Criteria:\n\n* Aim 1 Tissue\n\n  * Cases:\n\n    * Patient has a biopsy confirmed diagnosis of target histology\n    * Tissue samples from synchronous or metachronous primary cancers may be used as long as they are clearly of a different target organ.\n    * Tumors from patients with an underlying genetic disorder pre-disposing to cancer may be included as long as they are stratified from those without\n  * Controls:\n\n    * Patient does not have the diagnosis of target histology\n* Aim 2 Blood\n\n  * Cases:\n\n    * Patient has a biopsy confirmed diagnosis of target histology or radiographic criteria that are unequivocal for diagnosis (example, meets radiographic criteria for hepatocellular carcinoma)\n  * Controls:\n\n    * Patient does not have a documented diagnosis of cancer within 1 year following blood collections\n* Aim 3 Urine\n\n  * Cases:\n\n    * Patient has a biopsy confirmed diagnosis of target histology or radiographic criteria that are unequivocal for diagnosis (example, meets radiographic criteria for hepatocellular carcinoma)\n  * Controls:\n\n    * Patient does not have a diagnosis of the target histology\n\nExclusion Criteria:\n\n* Aim 1 Tissue\n\n  * Cases and Controls:\n\n    * Patient has had any transplants prior to tissue collection\n    * Patient has received chemotherapy class drugs within 5 years prior to tissue collection\n  * Cases:\n\n    * Patient has had radiation to the current target lesion prior to tissue collection\n    * Patient has multi-centric\u002Fmulti-focal breast cancer with differing genetic profiles (ER\u002FHER2\u002FPR status differ; if multiple masses are present and not all are tested then exclude patient)\n    * Patient has bilateral breast cancer\u002FDuctal carcinoma in situ (DCIS)\n* Aim 2 Blood\n\n  * Controls:\n\n    * Patient has known cancer prior to current sample acquisition (not including basal cell or squamous cell skin cancers) (if patient has not been seen or if information is not available, the patient is still eligible)\n  * Cases:\n\n    * Patient has known cancer outside of the target cancer 5 years prior to blood collection (not including basal cell or squamous cell skin cancers)\n    * Patient has received chemotherapy class drugs in the 5 years prior to blood collection\n    * Patient has had any prior radiation therapy to the target lesion prior to blood collection\n    * Patient has had an intervention to completely remove current target pathology\n    * The current target pathology is a recurrence\n    * Patient has had a biopsy to the target organ and\u002For lesion within 3 days before blood collection\n* Aim 3 Urine\n\n  * Patient has known cancer outside of the target cancer 5 years prior to urine collection (not including basal cell or squamous cell skin cancers)\n  * Patient has received chemotherapy class drugs in the 5 years prior to urine collection\n  * Patient has had any prior radiation therapy to the target lesion prior to urine collection\n  * Patient has had a biopsy to the target organ and\u002For lesion within 3 days before urine collection\n  * The current target pathology is a recurrence\n  * Patient has chronic indwelling urinary catheter\n  * Patient has had a urinary tract infection within the 14 days prior to sample collection\n  * If patient does not have a primary bladder, ureter or urethral cancer, patient has a history of bladder ureter, or urethral cancer\n  * Cases:\n\n    * Patient has had an intervention to completely remove current target pathology\n    * The current target pathology is a recurrence",{"count":51,"type":22},6150,"OBSERVATIONAL","This study explores the potential value of a new blood test approach for early detection of cancer.",[29,55],"Malignant Solid Neoplasm","2026-08-19",{"date":31,"type":34},{"date":59,"type":34},"2019-05-13",{"date":61,"type":22},"2028-05-15",{"name":63,"class":41},"Mayo Clinic",1,{"id":66,"slug":67,"hasResults":12,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},"100543232","biomarkers-to-predict-cancer-therapy-related-cardiotoxicity-100543232","NCT06353191","Biomarkers to Predict Cancer Therapy-related Cardiotoxicity","Biomarkers to Predict Cancer Therapy-Related Cardiotoxicity","Inclusion Criteria:\n\n* 18 years of age or older\n* Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy\n* One of the following:\n\n  * Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment\n  * Completed chemotherapy with no cardiotoxicity at least two years post treatment\n  * Patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include chemotherapy, immunotherapy, targeted therapy that have been associated with cardiac toxicity\n* An understanding of the protocol and its requirements, risks, and discomforts\n* The ability and willingness to sign an informed consent\n\nExclusion Criteria:\n\n\\- Inability on the part of the patient to understand the informed consent or be compliant with the protocol",{"count":73,"type":22},693,"This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.",[29,55],"2026-08-14",{"date":78,"type":34},"2026-08-18",{"date":80,"type":34},"2019-05-03",{"date":82,"type":22},"2031-12-31",{"name":63,"class":41},4,{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":64},"100652379","an-artificial-intelligence-powered-supportive-care-chatbot-to-address-the-supportive-care-needs-of-young-adult-cancer-survivors-100652379","NCT07772596","An Artificial Intelligence-Powered Supportive Care Chatbot to Address the Supportive Care Needs of Young Adult Cancer Survivors","Feasibility, Usability, and Acceptability of an AI-Powered MASCC Supportive Care Platform Among Young Adults With Cancer","Inclusion Criteria:\n\n* 18 - 39 years old\n* Able to speak\u002Fread English\n* Completed primary cancer treatment (e.g., surgery, radiation, chemotherapy, immunotherapy) at least one month prior to the time of consent. Although, participants will be eligible if they are receiving maintenance treatments\n* Report at least one moderate to severe symptom, side effect, or supportive care concern from cancer or its treatment\n* Able to access Wi-Fi\u002Finternet\n* Willing to complete surveys electronically\n\nExclusion Criteria:\n\n* Completed cancer treatment more than three years ago","39 Years",{"count":94,"type":22},30,[25],"This clinical trial studies whether an artificial intelligence (AI)-powered supportive care chatbot is helpful for addressing the supportive care needs of young adult cancer survivors. Young adult cancer survivors often experience ongoing and distressing symptoms following treatment, including extreme tiredness and lack of energy, anxiety, and difficulty sleeping. Young adult cancer survivors report a variety of strategies to self-manage these symptoms; however, there remains a gap in targeted interventions focused on the needs in young adult survivors. The AI-powered supportive care chatbot is designed to provide evidence-based information on supportive care for young adult cancer survivors. Users interact with the chatbot by entering free-text questions or selecting from predefined topics to receive tailored educational responses related to supportive care across the cancer continuum, including treatment effects, symptom management, care transitions, and life after cancer. The AI-powered supportive care chatbot may be an effective way to help address the supportive care needs of young adult cancer survivors.",[29,55],"NOT_YET_RECRUITING","2026-08-13",{"date":56,"type":34},{"date":102,"type":22},"2026-10-01",{"date":104,"type":22},"2028-10-01",{"name":106,"class":41},"University of Michigan Rogel Cancer Center",{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":64},"100634078","dental-cleaning-to-prevent-chronic-graft-versus-host-disease-100634078","NCT07535008","Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* T-replete allogeneic hematopoietic cell transplantation for any indication. History of prior transplantation is allowed. Any conditioning regimen is allowed\n* One of the following HCT donor types:\n\n  * 9\u002F10 or 10\u002F10 human leukocyte antigen (HLA)-matched unrelated donor\n  * Cord blood\n* Willing to have an in-person 1-year long-term follow-up (LTFU) visit including an oral medicine at Fred Hutch (FH)\n* Ability to understand and sign a written informed consent document (or legal representative)\n\nExclusion Criteria:\n\n* Edentulous state\n* Bone marrow as graft source\n* Use of post-transplantation cyclophosphamide (PTCy) or ruxolitinib as GVHD prophylaxis\n* Use of anti-thymocyte globulin (ATG) in conditioning",{"count":114,"type":22},45,[25],"This clinical trial evaluates the feasibility and effectiveness of a post-transplant dental cleaning for the prevention of chronic graft versus host disease (GVHD) in patients undergoing an allogeneic hematopoietic cell transplant (HCT). HCT is the only curative treatment for some types of blood cancer. Unfortunately, this approach can lead to the development of GVHD, which is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Some research has shown that the bacteria that is present in the dental plaque soon after transplant may affect the development of chronic GVHD. Dental cleanings prior to transplant are part of the normal standard of care for patients undergoing HCT. Adding an additional cleaning shortly after HCT may be effective for preventing the development of chronic GVHD.",[118,119,29],"Chronic Graft Versus Host Disease","Acute Graft Versus Host Disease","2026-08-10",{"date":122,"type":34},"2026-08-12",{"date":124,"type":34},"2026-06-11",{"date":126,"type":22},"2029-04-30",{"name":40,"class":41},{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":142,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":64},"100579650","phase-2-psilocybin-with-psychotherapy-for-improving-chronic-pain-in-cancer-patients-requiring-opioids-100579650","NCT06827054","Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids","Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring Opioids","Inclusion Criteria:\n\n* Age ≥ 18 and ≤ 75 years old\n* Diagnosis of active cancer, any stage\n* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n* Estimated prognosis of ≥ 3 months at the time of enrollment, determined by participant's primary oncologist or palliative physician\n* Diagnosis of moderate to severe pain (reported average pain score ≥ 4 on the 11-point Numerical Rating Scale) that is chronic (≥ 3 months) and secondary to cancer or cancer treatment\n* Pain regimen has been escalated to opioid therapy\n\n  * Participants must be on stable pain regimen for at least one month prior, with no intention to adjust pain regimen during the study period\n* Participants must be ≥ 4 weeks beyond treatments\u002Fprocedures that, in the opinion of the study physician, would significantly affect outcomes related to pain and physical function (e.g., surgery or radiation). Participants may otherwise receive cancer-directed treatment throughout the study period\n* Have no known procedures\u002Ftreatments scheduled in advance that would prohibit patient from completing or significantly delaying completion of the study\n\n  * The participant has no vacations or plans to be out of town during their study enrollment\n* Participants must not plan for additional treatments\u002Fprocedures that, in the opinion of the study physician, would significantly affect outcomes related to pain and physical function (e.g., surgery or radiation) for ≥ 4 weeks following psilocybin treatment initiation. Participants may otherwise receive cancer-directed treatment throughout the study period\n* No use of other illicit substances (excluding cannabis) within the past year based on self-report at screening and routine urine toxicology screen\n* Participants must be able to read, write, and speak English\n* Participants must be able to swallow pills\n* Agree to refrain from using any unprescribed psychoactive drugs, including alcoholic beverages, ≤ 24 hours of before each psilocybin administration. Exceptions include:\n\n  * Daily use of caffeine or nicotine\n  * Prescribed benzodiazepine medications and non-benzodiazepine sleeping medications will be allowed to continue through the study period for participants who have been on a stable dose of such a medicine for ≥ 6 weeks prior to screening\n* Participants using cannabis, including legal cannabis, for any purpose must agree to refrain from use beginning at two weeks before dosing and one week following completion of dosing (7-8 weeks total, dependent on frequency of prior use)\n\n  * Participants will not be withdrawn from the trial for a positive cannabis result during the initial screening drug test. However, participants who test positive for cannabis at the second drug test on visit 10 will be withdrawn from the trial\n* Participants must agree to be driven home after each experimental session and not drive or operate heavy machinery ≤ 16 hours of ingesting psilocybin\n* Participants must provide an emergency contact (relative, spouse, close friend, or other support person) willing and able to be reached by the investigators if the participant is unreachable by study staff or in an emergency\n* The participant agrees to take part in all study procedures, including the assessments, psychological evaluations, and dosing day requirements\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* Participants who are pregnant or breast-feeding\n* Participants of childbearing potential who decline to use a highly effective dual contraceptive method for the duration of the study\n* Participants with a condition impairing oral intake or digestive absorption\n* Cognitive impairment as defined by Montreal Cognitive Assessment (MOCA) score \\\u003C 23\n* Medical conditions or serious abnormalities of complete blood count, chemistries, or electrocardiography (ECG) that in the opinion of the study physician would preclude safe participation in the trial. Some examples include: congestive heart failure, valvular heart disease, recent acute myocardial infarction or evidence of ischemia, clinically significant arrhythmias (e.g., ventricular fibrillation, torsades) or clinically significant ECG abnormality (e.g. corrected QT interval using Fridericia's Correction Formula \\[QTcF\\] interval \\> 450 in males and \\> 470 in females), uncontrolled hypertension (systolic blood pressure \\[BP\\] ≥ 140 or diastolic BP ≥ 90 on three separate occasions), congenital long QT syndrome, renal dysfunction (i.e. creatinine clearance \\[CrCl\\] \\\u003C 40 mL\u002Fmin), liver cirrhosis or hepatic dysfunction (indicated by gamma-glutamyltransferase \\[GGT\\], aspartate aminotransferase \\[AST\\], or alanine aminotransferase \\[ALT\\] \\> 3 x ULN \\[upper limit of norm\\] or total bilirubin \\[bili\\] \\> 3.0 mg\u002Fdl, or Child Pugh over class C), paraneoplastic syndrome, respiratory failure, dementia, delirium, known cerebral aneurysm, seizure disorder, stroke\u002Ftransient ischemic attack (TIA) in past year, cancer with known central nervous system (CNS) involvement, previously treated brain metastasis, or other major CNS disease\n* Participants who have a personal history of, or a current diagnosis of the following: primary psychotic disorder, major depressive disorder with psychotic features, bipolar affective disorder type 1 or history of or current dissociative identity disorder\n* Participants who have an ongoing substance use disorder (defined as active in the past year)\n* Participants with first-degree relatives with schizophrenia or bipolar disorder may be eligible depending on their age and personal and family psychiatric history. The decision will be made by the principal investigator and study psychiatrist or on-call psychiatric provider based on risk assessment\n* Active suicidal behavior (interrupted or aborted attempt; preparatory acts) as assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) connotating either passive or active suicidal intent; OR one of the following:\n\n  * History of suicide attempt(s) within the past year (≤ 365 days)\n  * Have any suicidal ideation or thoughts, in the opinion of the study physician or principal investigator (PI), that presents a serious risk of suicidal or self-injurious behavior\n* Any contraindications to undergoing an fMRI scan, including having metal implants or metal fragments in the body\n* Participants who have hypersensitivity to the ingredients of the IMP (Investigational Medicinal Product) listed below:\n\n  * Indol alkaloids including psilocybin and psilocin\n  * Constituents of Psilocybe cubensis including protein, fats, carbohydrates, ergosterols, beta-glucan, and polyphenols\n  * Hydroxypropyl methylcellulose (HPMC) capsules\n* Participants who are taking medications with significant potential to interact with study medications will be exclusionary if they cannot be tapered. The taper interval will be at least five times the half-life. These medications include the following:\n\n  * Selective serotonin reuptake inhibitors (SSRIs)\n  * Serotonin and norepinephrine reuptake inhibitors (SNRIs)\n  * Tricyclic antidepressants (TCAs)\n  * Efavirenz\n  * Serotonin-acting dietary supplements (i.e., 5-hydroxy-tryptophan or St. John's wort)\n  * Centrally acting serotonergic agents (e.g., monoamine oxidase \\[MAO\\] inhibitors)\n  * Antipsychotics for a psychiatric disorder (e.g., first and second generation)\n\n    * Antipsychotics that are utilized for nausea, insomnia, or other non-psychiatric condition will be permitted, but patients will be asked to refrain from use 8 hours prior to dosing sessions\n  * Mood stabilizers (e.g., lithium, valproic acid)\n  * Aldehyde dehydrogenase inhibitors (e.g., disulfiram)\n  * Significant inhibitors of UGT 1A9 or UGT 1A10\n* Use of serotonergic hallucinogens (e.g., psilocybin, lysergic acid diethylamine \\[LSD\\]) within the past 12 months or significant lifetime use (\\> 25 uses)\n* Those with a history of prior violent and\u002For drug-related felonies\n* Those currently incarcerated will be excluded\n* Unwilling or unable to follow protocol requirements\n* Any social circumstance which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug","75 Years",{"count":137,"type":22},20,[139],"PHASE2","This phase II trial studies whether psilocybin with psychotherapy is safe and if it works for improving chronic pain in cancer patients who require opioids to manage their pain. Psilocybin is taken from the mushroom Psilocybe mexicana. Psilocybin acts on the brain to cause hallucinations (sights, sounds, smells, tastes, or touches that a person believes to be real but are not real). This may impact a patient's \"total pain\", a view that accounts for the psychological, spiritual, and social factors that contribute to their experience of pain. Psychotherapy uses methods such as discussion, listening, and counseling to help patients change the way they react to environmental triggers that may cause a negative reaction. Giving psilocybin with psychotherapy may be safe and helpful for improving chronic pain in cancer patients who require opioids to manage their pain.",[29,55],{"date":122,"type":34},{"date":144,"type":22},"2026-09-15",{"date":146,"type":22},"2027-05-05",{"name":148,"class":41},"Roswell Park Cancer Institute",{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":23,"phases":158,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":64},"100602667","a-virtual-community-health-educator-for-increasing-clinical-trial-referrals-among-cancer-patients-and-their-caregivers-100602667","NCT07126496","A Virtual Community Health Educator for Increasing Clinical Trial Referrals Among Cancer Patients and Their Caregivers","Precision Clinical Trial Recruitment to Promote Cancer Health Equity Across Florida (Aims 2 & 3)","Inclusion Criteria:\n\n* Individuals Diagnosed with Cancer\n\n  * 18 years or older\n  * Must have received a cancer diagnosis at any point in your life\n  * Able to understand English or Spanish\n* Care Partners\n\n  * Must be a care partner (also known as caregiver, carer, supporter, helper, aide, assistant, companion, attendant, advocate, or family caregiver) of an adult who has received a cancer diagnosis\n  * Must be actively involved in the decision-making process OR care of a person diagnosed with cancer\n  * Must be 18 years or older\n\nExclusion Criteria:\n\n* Self-reported: people who are currently or have been in a cancer clinical trial within the last 3 years",{"count":157,"type":22},2000,[25],"This clinical trial studies how well a virtual community health educator (vCHE) works in increasing clinical trial referrals for patients with cancer and their caregivers. Low enrollment of underrepresented and underserved populations in cancer clinical trials has led to disparities in intervention development and implementation. One approach to recruiting diverse populations to cancer clinical trials is community health educators. However, community health educator interventions are costly and difficult to implement. vCHEs are photo-realistic virtual agents that provide personalized guidance and support to users. They are designed to mimic real-life community health workers, offering culturally and linguistically tailored information to users. They can communicate in English or Spanish and are available in diverse genders and racial\u002Fethnic backgrounds. vCHEs may be able to increase the enrollment of diverse participants into cancer clinical trials.",[29,55],"2026-08-07",{"date":163,"type":34},"2026-08-11",{"date":165,"type":34},"2025-05-20",{"date":167,"type":22},"2027-08-31",{"name":63,"class":41},{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":42},"100578945","phase-2-remdesivir-for-the-treatment-of-upper-respiratory-tract-infection-due-to-rsv-in-immunocompromised-individuals-100578945","NCT06817889","Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals","An Open-Label Study to Assess the Safety and Efficacy of Remdesivir for Treatment of Symptomatic Laboratory-Confirmed Respiratory Syncytial Virus Infection of the Upper Respiratory Tract in Patients Receiving Cellular or Bispecific Antibody Therapies","Inclusion Criteria:\n\n* Aged ≥ 18 years\n* Willing and able to provide written informed consent, or with a legal representative who can provide informed consent (where locally approved)\n* RSV confirmed by local lab testing via nucleic acid amplification test (e.g. polymerase chain reaction \\[PCR\\] or respiratory viral panel \\[RVP\\]) using an upper respiratory tract sample collected within the 5 days prior to day 1 (RDV dosing)\n* Symptomatic RSV infection of the upper respiratory tract, with symptom onset and positive microbiologic testing within the 5 days prior to day 1 (RDV dosing). Symptomatic RSV infection is defined as having new upper respiratory symptom(s) or worsening of a pre-existing upper respiratory symptom (if chronic and associated with a previously existing diagnosis, such as chronic lung disease, chronic rhinorrhea, or seasonal allergies)\n* Receiving treatment for a refractory or relapsed hematologic malignancy, or received a hematopoietic cell transplant (HCT), chimeric antigen receptor T cell therapy (CARTx), or bispecific antibody (bsAb) therapy within the past 365 days (relative to RSV diagnosis date)\n* Categorized as moderate-risk (overall score 3-6) or high-risk (overall score 7-10) per an adapted version of the Immunodeficiency Scoring Index (ISI) for RSV, as below, relative to the day of RSV diagnosis:\n\n  * 1 point:\n\n    * Recent (within the prior 30 days) allogeneic HCT, autologous HCT, or CARTx\n    * Corticosteroids within the prior 30 days for management of graft versus host disease (GVHD) or cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).\n  * 2 points:\n\n    * Age ≥ 40 years\n  * 3 points:\n\n    * Absolute neutrophil count (ANC) \\\u003C 500 cells\u002FμL within the prior 7 days\n    * Absolute lymphocyte count (ALC) \\\u003C 200 cells\u002FµL within the prior 7 days\n* Oxygen saturation (SpO2) 93% or greater on room air and at rest (to be measured after participant has rested in a quiet room for ≥ 2 minutes, with oxygen \\[O2\\] saturation probe on finger or earlobe for ≥ 1 minute, with saturation reading remaining ≥ 93%) at screening\n* Willingness to take study drug and complete necessary study procedures\n* Participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception as described\n\nExclusion Criteria:\n\n* Received or receiving an approved or authorized direct-acting antiviral therapy with potential efficacy against RSV (e.g. ribavirin) for ≥ 24 hours within the prior 7 days, and\u002For expected to receive anti-RSV direct-acting antiviral therapies for RSV during the course of the study at the time of screening\n* Received or receiving investigational direct-acting antiviral therapies against RSV for the current RSV episode\n* Received any investigational anti-RSV monoclonal antibodies or off-label use of approved anti-RSV monoclonal antibodies within \\\u003C 4 months or \\\u003C 5 half-lives, whichever is longer, before screening, or expected to receive anti-RSV monoclonal antibodies during the course of the study at the time of screening\n* Received an RSV vaccine after cellular therapy or after starting the current antitumor therapeutic regimen\n* Participation in any other concurrent clinical trial of an experimental treatment for RSV, including RSV vaccines\n* Alanine aminotransferase (ALT) ≥ 5 times the upper limit of normal within 7 days prior to screening\n* Unable to tolerate nasal sampling required for this study, as determined by the investigator (e.g., history of significant epistaxis, nasopharyngeal anatomical abnormalities, nasal or sinus surgery)\n* A life expectancy of three months or less, as determined by the investigator\n* Pregnant, as determined by a Point-of-Care urine pregnancy test or reported by the patient or their electronic health record within 7 days of screening\n* Receiving, requiring, or expected to require supplemental oxygen for RSV-related illness or SpO2 \\\u003C 93% at rest \\\u003C 24 hours prior to study drug administration\n* Previous infection or treatment for RSV, or previous treatment or hospitalization for another respiratory viral infection, \\\u003C 28 days before screening\n* Documented positive test for other respiratory viruses concomitantly (limited to influenza, parainfluenza, adenovirus, human metapneumovirus, or coronavirus \\[including SARS-CoV-2\\]) ≤ 7 days prior to screening, as determined by local testing (additional testing not required)\n* Clinically significant bacteremia or fungemia ≤ 7 days prior to screening and not adequately treated, as determined by the investigator\n* Clinically significant bacterial, fungal, or viral pneumonia within two (2) weeks prior to screening and not adequately treated, as determined by the investigator\n* Clinically significant symptoms of CRS or ICANS within the prior 72 hours before screening that is not adequately controlled, as determined by the investigator\n* Any inability to take study drug or comply with study procedures that, in the opinion of the investigator, would make the participant unsuitable for the study\n* Known hypersensitivity or allergy to the study drug, its metabolites, or formulation excipients",{"count":177,"type":22},60,[139],"This phase II trial tests how well remdesivir works for treatment of respiratory syncytial virus (RSV) infection of the upper respiratory tract in patients receiving cellular or bispecific antibody therapy. Cellular or bispecific antibody therapies cause suppression of the immune system, making infections more frequent and reducing the body's ability to fight the infections. RSV infections are one of the most common respiratory infections in immunocompromised individuals and can cause significant pneumonia and even death. Remdesivir is in a class of medications called antivirals. It works by stopping viruses from spreading in the body.",[29,181,182],"Autoimmune Disease","Respiratory Syncytial Virus Infection","2026-08-05",{"date":185,"type":34},"2026-08-06",{"date":187,"type":34},"2025-12-23",{"date":189,"type":22},"2027-11-30",{"name":40,"class":41},{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":200,"conditions":201,"keywords":202,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":64},"100583786","investigating-memory-and-physical-activity-after-cancer-treatment-in-survivors-of-adolescent-and-young-adult-cancers-100583786","NCT06880861","Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers","IMPACT","Inclusion Criteria:\n\n* Adults (aged 18+ years)\n* Primary diagnosis of cancer when 15-39 years-old\n* Access to a desktop computer or laptop with reliable internet access\n* No gross motor impairments that prohibit ambulation\n* Willing to complete study requirements\n* English speaking\n\nExclusion Criteria:\n\n* Diagnosed with nonmelanoma skin cancer only\n* Not diagnosed with cancer in adolescent and young adult (AYA) age range of 15-39 years\n* Scheduled travel during the study period that is not indicative of individual's normal schedule",{"count":199,"type":22},150,"This study evaluates relationships among physical activity, thinking, and memory after cancer treatment in survivors of adolescent and young adult cancers.",[29,55],[203,204,205,206,207,208,209],"cancer","adolescent","young adult","cognition","memory","exercise","physical activity","2026-08-03",{"date":212,"type":34},"2026-08-04",{"date":214,"type":34},"2025-07-01",{"date":216,"type":22},"2026-09-30",{"name":63,"class":41},{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":23,"phases":227,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":246},"100492388","phase-1-testing-the-combination-of-the-anti-cancer-drugs-temozolomide-and-m1774-to-evaluate-their-safety-and-effectiveness-100492388","NCT05691491","Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness","A Phase 1\u002F2 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774","Inclusion Criteria:\n\n* Patients must have histologically or cytologically confirmed diagnosis of metastatic advanced cancer.\n* In dose escalation, any solid tumor patients with either O6-methylguanine DNA methyltransferase (MGMT) promoter hypermethylation positivity on testing \u002F pre-screening of archival tissue OR an extracranial solid tumor where TMZ is considered a standard of care per National Comprehensive Cancer Network (NCCN) guidelines (neuroendocrine tumor, small cell lung cancer, melanoma or soft tissue sarcoma). The tumor lesion must be safely accessible to a mandatory biopsy. Patients with MGMT promoter hypermethylated colorectal cancer must be mismatch repair proficient \u002F microsatellite stable.\n* In phase 2, only patients with mismatch repair proficient \u002F microsatellite stable colorectal cancer that have MGMT promoter hypermethylation positivity on pre-screening of archival tissue will be eligible.\n* In dose escalation, patients must have progressed after treatment with all available therapies including immunotherapies for metastatic disease that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment. Patients may not have previously received temozolomide or an ataxia telangiectasia and rad3-related (ATR) inhibitor.\n* For patients with mismatch repair proficient \u002F microsatellite stable colorectal cancer in the phase 2 portion, patients must have received prior therapy with 1 or more systemic therapies in the metastatic setting that includes 5-fluorouracil, irinotecan, and oxaliplatin. Patients with microsatellite stable colorectal cancer (mCRC) need to have had exposure, unless contraindicated, to all 3 of oxaliplatin, irinotecan, and fluoropyrimidine (FP).\n\nThe use of 5-fluorouracil and oxaliplatin in the adjuvant setting is acceptable, provided the development of metastatic disease was less than 6 months after the completion of adjuvant therapy.\n\nPatients with a prior hypersensitivity reaction to oxaliplatin in the adjuvant setting do not require retreatment in the metastatic setting.\n\n* Age \\>=18 years. Because no dosing or adverse event data are currently available on the use of M1774 in combination with temozolomide in patients \\\u003C 18 years of age, children are excluded from this study.\n* Measurable disease on CT and\u002For MRI per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria.\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 2 (or Karnofsky \\>= 60%).\n* Hemoglobin \\>=10 g\u002FdL (No blood transfusions are allowed within 14 days of cycle 1 day 1 \\[C1D1\\]).\n* White blood cells (WBC) \\> 3 x 10\\^9\u002FL.\n* Absolute neutrophil count \\>= 1,500\u002FmcL.\n* Platelets \\>= 100,000\u002FmcL.\n* Total bilirubin =\\\u003C 1.5 x institutional upper limit of normal (ULN).\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\])\u002Falanine-aminotransferase (ALT) (serum glutamic-pyruvic transaminase \\[SGPT\\]) =\\\u003C 3 x institutional ULN except for when liver metastases are present, in which case they must be =\\\u003C 5 x institutional ULN.\n* Glomerular filtration rate (GFR) \\>= 60 mL\u002Fmin\u002F1.73 m\\^2.\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression for 4 weeks.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.\n* The effects of M1774 on the developing human fetus are unknown. For this reason and because ATR inhibitors agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 6 months after completion of M1774 administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of M1774 administration.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> grade 1) with the exception of alopecia and neuropathy, which may be =\\\u003C grade 2.\n* History of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to M1774 or temozolomide, including dacarbazine.\n* Patients with uncontrolled intercurrent illness.\n* Pregnant women are excluded from this study because M1774 is an ATR inhibiting agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with M1774 breastfeeding should be discontinued if the mother is treated with M1774. These potential risks also apply to temozolomide.\n* Patients with a prior history of ataxia telangiectasia.\n* Patients who are not able to swallow orally administered medication or have gastrointestinal disorders likely to interfere with absorption of the study medication.\n* Patients who cannot discontinue proton-pump inhibitors (PPIs) while taking M1774. H-2 receptor antagonists are allowed but should not be taken within 12 hours before or 2 hours after M1774. Antacids are also allowed, but should not be taken 2 hours before 2 hours after M1774.\n* Extensive RT involving greater than 30% of the bone marrow is not permitted during the study.\n* A Fridericia's correction formula (QTcF) \\> 480 ms is exclusionary given the potential for QT.",{"count":226,"type":22},42,[228,139],"PHASE1","This phase I\u002FII trial studies the side effects and best dose of temozolomide and M1774 and how well they works in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and may have spread to nearby tissue, lymph nodes, or distant parts of the body (advanced). Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill tumor cells and slow down or stop tumor growth. M1774 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Adding M1774 to temozolomide may shrink or stabilize cancer for longer than temozolomide alone.",[28,231,29,232,233,234,235],"Advanced Microsatellite Stable Colorectal Carcinoma","Metastatic Malignant Solid Neoplasm","Metastatic Microsatellite Stable Colorectal Carcinoma","Stage III Colorectal Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","2026-07-30",{"date":238,"type":34},"2026-07-31",{"date":240,"type":34},"2023-09-28",{"date":242,"type":22},"2027-03-01",{"name":244,"class":245},"National Cancer Institute (NCI)","NIH",23,{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":23,"phases":256,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":64},"100614857","phase-2-the-cancer-connected-access-and-remote-expertise-beyond-walls-program-to-provide-in-home-cancer-treatment-and-improve-treatment-satisfaction-in-cancer-patients-living-in-the-florida-panhandle-and-surrounding-areas-100614857","NCT07285044","The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas","Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Pilot, Phase 2 Clinical Trial to Evaluate Administration of Cancer-Directed Therapy in the Patient's Homes Versus in Clinic in the Florida Panhandle and Surrounding Areas","Inclusion Criteria:\n\n* Patient has had adequate tolerability of their clinical standard of care treatment, in the opinion of their treating physician, and no clinically significant drug-related reactions occurred prior to consent\n* Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) Food and Drug Administration (FDA)-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g. National Comprehensive Cancer Network \\[NCCN\\], American Society of Clinical Oncology \\[ASCO\\], American Society of Hematology \\[ASH\\], etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines\n* A social stability screener, used per standard of care, indicates patient is appropriate to participate in the CCBW program\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2 or 3 at the discretion of the treating physician\n* Female or male patients age \\>= 18 years at the time of consent\n* Willing and able to comply with the study protocol in the investigator's judgement\n* Patients with histologically confirmed malignancy who are currently receiving treatment with one of the eligible treatment regimens. Patients with hepatocellular carcinoma (HCC) are eligible based on imaging diagnosis alone: histologic confirmation is not required.\n\n  * Note: patients diagnosed with any of the following disease types may receive any of the eligible regimens listed. Additionally, patients receiving hormonal or immunotherapy, such as nivolumab or pembrolizumab, may receive these infusions in home supplemental to any of the regimens identified. Co-administration with hormonal agents such as anti-androgens, poly(ADP-ribose) polymerase (PARP) inhibitors, oral gonadotrophin releasing hormone (GnRh) antagonists, estrogens, selective estrogen receptor modulators (SERMs), or aromatase inhibitors are allowed, however combinations of oral regimens only are not permitted. Patients may receive any combination of any listed medications or regimens\n  * Eligible disease cancer types:\n\n    * Amyloidosis\n    * Basal cell carcinoma\n    * Biliary\n    * Bladder\n    * Breast\n    * Cervical\n    * Colorectal\n    * Endometrial\n    * Fallopian tube\n    * Gastroesophageal\n    * Glioblastoma\n    * Head and neck\n    * Hepatocellular\n    * Hodgkin lymphoma\n    * Lung\n    * Mantle cell lymphoma\n    * Merkle cell carcinoma\n    * Multiple myeloma\n    * Melanoma\n    * Myelodysplastic syndrome\n    * Ovarian\n    * Pancreatic\n    * Peritoneal\n    * Prostate\n    * Renal cell carcinoma\n    * Squamous cell carcinoma\n    * Urothelial carcinoma\n  * Eligible regimens\n\n    * Atezolizumab +\u002F- bevacizumab\n    * Avelumab\n    * Bevacizumab\n    * Bortezomib\n    * Cemiplimab\n    * Daratumumab +\u002F- bortezomib\n    * Darbepoetin alpha\n    * Degarelix\n    * Denosumab (Xgeva)\n    * Durvalumab\n    * Fluorouracil +\u002F- bevacizumab\n    * Fulvestrant\n    * Goserelin\n    * Ipilimumab +\u002F- Nivolumab\n    * Lanreotide\n    * Leuprolide\n    * Nivolumab\n    * Nivolumab + relatlimab\n    * Octreotide\n    * Pembrolizumab\n    * Pertuzumab +\u002F- trastuzumab\n    * Trastuzumab +\u002F- pertuzumab\n    * Zoledronic acid (Zometa)\n* Willingness to follow birth control requirements for females and males of reproductive potential\n* Resides within the Florida Panhandle and surrounding area serviced by the at-home healthcare supplier utilized for the study and a paramedic network\n* Patient's residence has an existing Wi-Fi connection or can be connected using using a mobile Wi-Fi device provided as part of the program so as to enable a reliable connection with the remote CCBW Command Center at Mayo Clinic\n* Patients who, according to documentation from their treating provider, plan to continue the eligible treatment regimen they are currently prescribed for \\>= 12 weeks from the time of registration\n* Provide written informed consent\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\n\nExclusion Criteria:\n\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Receiving any investigational agent which would be considered as a treatment for the primary neoplasm.\n\n  * Note: oral concomitant medications for oncologic indications will be maintained per standard of care treatment and not considered part of the trial. Any nononcologic medication, regardless of route of administration will be maintained per standard of care treatment and also not considered part of the trial; therefore, patients receiving oral anti-cancer or other medications per standard of care treatment in addition to any of the medications listed are considered eligible for this trial\n* Individuals who require continuous (24\u002F7) assistance with daily living and are unable to independently manage the technology required for study participation, unless a caregiver is available and willing to provide consistent support throughout the study\n* Current inpatient hospitalization (excluding admission to the Advanced Care at Home program)",{"count":255,"type":22},27,[139],"This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.",[259,260,261,262,263,264,265,266,267,268,269,270,29,271,272,273,55,274,275,276,277,278,279,280,281,282,283,284,285],"Amyloidosis","Basal Cell Carcinoma","Biliary Tract Carcinoma","Bladder Carcinoma","Breast Carcinoma","Cervical Carcinoma","Colorectal Carcinoma","Endometrial Carcinoma","Fallopian Tube Carcinoma","Gastroesophageal Junction Carcinoma","Glioblastoma","Head and Neck Carcinoma","Hepatocellular Carcinoma","Hodgkin Lymphoma","Lung Carcinoma","Mantle Cell Lymphoma","Melanoma","Merkel Cell Carcinoma","Multiple Myeloma","Myelodysplastic Syndrome","Ovarian Carcinoma","Pancreatic Carcinoma","Primary Peritoneal Carcinoma","Prostate Carcinoma","Renal Cell Carcinoma","Squamous Cell Carcinoma","Urothelial Carcinoma","2026-07-28",{"date":236,"type":34},{"date":289,"type":34},"2025-12-18",{"date":291,"type":22},"2026-12-18",{"name":63,"class":41},{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":23,"phases":302,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":310,"locationsCount":64},"100559836","genetic-testing-for-the-prevention-of-cancer-in-american-indian-communities-juniper-trial-100559836","NCT06569316","Genetic Testing for the Prevention of Cancer in American Indian Communities (JUNIPER Trial)","Journey to Understanding - American Indian Peoples Engagement in Cancer Research Arizona (JUNIPER)","Inclusion Criteria:\n\n* Male or female adults \\>= 18 years of age\n* Cancer patient undergoing active treatment or a cancer survivor\n* Self-identify as American Indian\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Individuals who are under 18 years of age\n* Prisoners",{"count":301,"type":22},300,[25],"This clinical trial is studying the genetic changes in cells associated with different types of cancer in American Indian (AI) populations in the Southwest to improve cancer screening, precision prevention, and therapeutic intervention for individual in these communities. AI tribes have much lower rates of cancer screening, have more limited access to healthcare, are more often diagnosed at later stages of disease, and have the poorest outcomes in all types of cancer when compared to any other racial and ethnic group in the United States. Due to these significant cancer health disparities, AIs have been understudied and little is known about the molecular characterization of tumors arising in AIs. Undergoing genetic testing of tumors may improve cancer outcomes in AI participants and communities.",[29,55],{"date":306,"type":34},"2026-07-29",{"date":308,"type":34},"2024-09-27",{"date":167,"type":22},{"name":63,"class":41},{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":23,"phases":319,"briefSummary":320,"conditions":321,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":64},"100559525","community-based-exercise-and-nutrition-training-and-education-program-for-cancer-survivors-100559525","NCT06565260","Community-Based Exercise and Nutrition Training and Education Program for Cancer Survivors","Feasibility of a Community-Based Cancer Survivor Exercise and Nutrition Education Program: Effects on Self-Efficacy, Quality of Life and Functional Performance","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Have had a previous cancer diagnosis and completed all therapy OR are a caregiver for a patient who has had a previous cancer diagnosis.\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related interventions.\n\nExclusion Criteria:\n\n* Have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia including atrial fibrillation (AFIB), multiple myeloma, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Have orthopedic or neuromuscular disorders or arthritis that preclude participation in exercise.\n* Are pregnant or nursing.\n* History of a stem cell transplant.\n* Currently on steroids.\n* Unwilling or unable to follow protocol requirements.\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to participate in the study.",{"count":199,"type":22},[25],"This clinical trial evaluates whether a supervised community-based exercise and nutrition program is usable and effective for improving cancer survivors' confidence for maintaining their physical activity and nutrition. Cancer survivors often experience problems with the musculoskeletal system (bones, joints, muscles, connective tissue), the cardiopulmonary system (heart, blood vessels and lungs) and the metabolic system (how the body's cells change food into energy) following treatment. There is substantial evidence that physical activity, diet, and weight management can improve quality of life (emotional and physical well-being) and physical fitness. Information gathered from this study may help researchers determine whether participating in a community-based exercise\u002Fnutrition training and education program may improve levels of fitness, cardiovascular health, and quality of life for cancer survivors.",[29,55],{"date":306,"type":34},{"date":324,"type":22},"2026-09-01",{"date":326,"type":22},"2029-08-30",{"name":148,"class":41},{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":23,"phases":336,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":344,"locationsCount":64},"100649573","tele-hope-a-telehealth-pharmacist-opioid-patient-education-pilot-study-100649573","NCT07737314","Tele-HOPE: A Telehealth Pharmacist Opioid Patient Education Pilot Study","Inclusion Criteria:\n\n* Age ≥ 18 years, consistent with the population of patients treated at Fred Hutch Cancer Center\n* A cancer diagnosis\n* Established care in the Fred Hutch Palliative Care Clinic (≥ 1 visit with a Fred Hutch palliative care physician or advanced practice provider within the past 12 months)\n* Prescribed opioids, defined as either ≥ 1 opioid prescription within the past 6 months documented in the Washington Prescription Drug Monitoring Program (PDMP), or a new opioid prescription initiated by the referring palliative care provider at the time of referral\n* Ability to understand and willingness to agree to an electronic consent document\n* Enrolled in MyChart and ability to participate in a telehealth video visit\n\nExclusion Criteria:\n\n* Patients who prefer a language other than English for healthcare, as the session will be conducted live and cannot currently be offered in other languages",{"count":335,"type":22},50,[25],"This clinical trial will evaluate the feasibility, acceptability, and potential efficacy of a palliative care pharmacist-led group telehealth opioid education session for palliative care patients prescribed opioids for cancer-related pain. While opioids are commonly used in palliative care settings to manage cancer-related pain, their significant side effects, complicated administration requirements, and concerns about addiction can make it challenging for patients to use opioids safely and effectively. Some patients may even avoid opioids altogether because of these concerns, even when opioids are clinically indicated, leading to poor symptom control. To address these challenges, a telehealth education session was developed as a clinical initiative by a palliative care pharmacist, addressing safe and effective opioid management. Educational priorities and session content were informed by a survey of interdisciplinary palliative care clinicians that identified barriers and facilitators to opioid education and key patient educational needs. Patients scheduled to attend a pharmacist-led group telehealth opioid education session who enroll in the study will complete a survey before the session and another survey afterward. This study will assess the feasibility and acceptability of delivering the intervention, as well as its preliminary effects on opioid knowledge and self-efficacy. If feasible and acceptable, this pharmacist-led telehealth education model could represent a scalable strategy to improve opioid management for patients with cancer-related pain.",[29,55],"2026-07-27",{"date":236,"type":34},{"date":342,"type":22},"2026-11-01",{"date":167,"type":22},{"name":40,"class":41},{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":135,"enrollmentInfo":352,"targetDuration":4,"studyType":23,"phases":354,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":366,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":42},"100594521","phase-1-a-vaccine-cmv-mva-triplex-vaccine-for-the-enhancement-of-cmv-specific-immunity-and-the-prevention-of-cmv-viremia-in-patients-undergoing-haploidentical-hematopoietic-stem-cell-transplant-100594521","NCT07020533","A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant","A Phase 1b Trial of CMV-MVA Triplex Vaccine in Haploidentical Stem Cell Donors and Recipients to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients of Hematopoietic Stem Cell Transplant","Inclusion Criteria:\n\n* DONORS: Documented informed consent of the participant. This can be done in person or informed consent can be obtained remotely.\n\n  * Remote consent, when appropriate, will be obtained per institutional guidelines.\n  * Assent, when appropriate, will be obtained per institutional guidelines.\n  * Adult subjects who require a legally authorized representative (LAR) will not be permitted to be enrolled under this protocol.\n* DONORS: Age: 18 - 75.\n* DONORS: Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n* DONORS: Agreement by females and males of childbearing potential\\* to use an effective method of birth control (hormonal or barrier method) or abstain from heterosexual activity prior to study entry and for up to 90 days post-vaccination.\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only).\n* RECIPIENTS: Documented informed consent of the participant and\u002For legally authorized representative. This can be done in person or informed consent can be obtained remotely.\n\n  * Remote consent, when appropriate, will be obtained per institutional guidelines.\n  * Assent, when appropriate, will be obtained per institutional guidelines.\n  * Adult subjects who require a legally authorized representative (LAR) will not be permitted to be enrolled under this protocol.\n* RECIPIENTS: Participant must be willing to comply with study and\u002For follow-up procedures, including willingness to be followed for one year post-HCT.\n* RECIPIENTS: Age: 18 - 75.\n* RECIPIENTS: Planned peripheral blood stem cell (PBSC) or bone marrow (BM) HCT for the treatment of the following hematologic malignancies:\n\n  * Lymphoma (Hodgkin and Non-Hodgkin).\n  * Myelodysplastic syndrome.\n  * Acute lymphoblastic leukemia in first or second remission (for acute lymphoblastic leukemia\u002Flymphoblastic lymphoma, the disease status must be in hematologic remission by bone marrow and peripheral blood. Persistent lymphadenopathy on computed tomography (CT) or CT\u002Fpositron emission tomography(PET) scan without progression is allowed.)\n  * Acute myeloid leukemia in first or second remission.\n  * Chronic myelogenous leukemia in first chronic or accelerated phase, or in second chronic phase.\n  * Other hematologic malignancies judged appropriate by the clinical principal investigators (PIs), including chronic lymphocytic leukemia, myeloproliferative disorders and myelofibrosis. Patients with multiple myeloma and those with non-malignant disease such as aplastic anemia are excluded\\*\\*.\n\n    * Adult cases of multiple myeloma (MM) are excluded as HCT is not standard of care for MM and is only performed in very advanced cases with an associated high risk of relapse and non-relapse mortality (NRM). Adults with aplastic anemia are excluded because their standard management includes T cell depletion with agents such as antithymocyte globulin (ATG), which is not permissible on this protocol. Patients undergoing a second haploHCT are not eligible (patients who have undergone a previous autologous HCT are eligible).\n* RECIPIENTS: Patients receiving myeloablative (MA) or reduced intensity conditioning (RIC) are allowed.\n* RECIPIENTS: CMV seropositive.\n* RECIPIENTS: Eligible haploidentical donors will have 2-4 mismatches if human leukocyte antigen (HLA)-A, -B, -C, and -DRB1 typing is used; 2-5 mismatches if HLA-A, -B, -C, -DRB1, and -DQB1 typing is used; and 2-6 mismatches if HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 typing is used. A unidirectional mismatch in either the graft versus host or host versus graft direction is considered a mismatch. The donor and recipient must demonstrate that they are a full haplotype match by being identical at a minimum of one allele (at high resolution deoxyribonucleic acid \\[DNA\\]-based typing) at the following genetic loci: HLA-A, -B, -C, and DRB1 if 8 allele typing is used; HLA-A, -B, -C, -DRB1, and -DQB1 if 10 allele typing is used; and HLA-A, -B, -C, -DRB1-, DQB1, and -DPB1 is 12 allele typing is used.\n* RECIPIENTS: Planned HCT with minimal to no-T cell depletion of graft.\n* RECIPIENTS: Conditioning and immunosuppressive regimens according to institutional guidelines are permitted.\n* RECIPIENTS: Total bilirubin ≤ 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease) (to be performed within 45 days prior to day 1 of protocol therapy).\n* RECIPIENTS: Aspartate aminotransferase (AST) =\\\u003C 2.5 x ULN (to be performed within 45 days prior to day 1 of protocol therapy).\n* RECIPIENTS: Alanine aminotransferase (ALT) =\\\u003C 2.5 x ULN (to be performed within 45 days prior to day 1 of protocol therapy).\n* RECIPIENTS: Estimated creatinine clearance acceptable per institutional guidelines (to be performed within 45 days prior to day 1 of protocol therapy).\n* RECIPIENTS: Left ventricular ejection fraction (LVEF) ≥ 50%.\n\n  * Note: To be performed within 45 days prior to day 1 of protocol therapy.\n* RECIPIENTS: If able to perform pulmonary function tests: forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and carbon monoxide diffusing capability (DLCO) (diffusion capacity) ≥ 50% of predicted (corrected for hemoglobin).\n\n  * If unable to perform pulmonary function tests: Oxygen (O2) saturation \\> 92% on room air.\n  * Note to be performed within 45 days prior to day 1 of protocol therapy.\n* RECIPIENTS: Seronegative for HIV antigen (Ag)\u002Fantibody (Ab) combination (combo), hepatitis c virus (HCV)\\*, active hepatitis b virus (HBV) (surface antigen negative) and syphilis (RPR) within 2 months of registration and no history of disseminated cutaneous human papillomavirus (HPV) related disease.\n\n  * If seropositive for HIV, HCV or HBV, nucleic acid quantitation must be performed. Viral load must be undetectable.\n* RECIPIENTS: Meets other institutional and federal requirements for infectious disease titer requirements.\n\n  * Note Infectious disease testing to be performed within 45 days prior to day 1 of protocol therapy.\n* RECIPIENTS: Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (to be performed within 45 days prior to day 1 of protocol therapy).\n* RECIPIENTS: Agreement by females and males of childbearing potential\\* to use an effective method of birth control (hormonal or barrier method) or abstain from heterosexual activity prior to study entry and up to 90 days post-HCT.\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only).\n\nExclusion Criteria:\n\n* DONORS: Any prior transplant to day 1 of protocol therapy (day 1 defined as the day after donors receive the Triplex vaccine).\n* DONORS: Chemotherapy, radiation therapy, biological therapy, immunotherapy within 21 days prior to day 1 of protocol therapy.\n* DONORS: Receipt of any vaccine (licensed or investigational) within 30 days prior to and after the study vaccine.\n* DONORS: Unfit to undergo standard stem cell mobilization and apheresis e.g. abnormal blood counts, history of stroke, uncontrolled hypertension.\n* DONORS: Sickling hemoglobinopathy including hemoglobin (Hb)SS, HbAS, HbSC.\n* DONORS: Donors with impaired cardiac function are excluded. Electrocardiography is routine for potential HCT donors over 60 years old and those with a history of heart disease. Subjects in whom cardiac function is abnormal (excluding 1st degree branch block, sinus bradycardia, sinus tachycardia or non-specific T wave changes) are ineligible for Triplex vaccination.\n* DONORS: Severe psychiatric illness. Mental deficiency sufficiently severe as to make compliance with the donation procedure unlikely and making informed consent impossible.\n* DONORS: Females only: Pregnant or breastfeeding.\n* DONORS: Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.\n* DONORS: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics).\n* RECIPIENTS: Any prior investigational CMV vaccine.\n* RECIPIENTS: Experimental anti-CMV chemotherapy in the last 6 months.\n* RECIPIENTS: Live attenuated vaccines (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Medically indicated subunit (Engerix-B for HBV; Gardasil for HPV) or killed vaccines (e.g. influenza, pneumococcal, or allergy treatment with antigen injections) (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Allergy treatment with antigen injections (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Alemtuzumab or any equivalent in vivo T-cell depleting agent (or CD34+ selection) (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Antiviral medications with known therapeutic effects on CMV such as ganciclovir (GCV)\u002Fvalganciclovir (VAL), foscarnet (FOS), cidofovir, CMX-001, maribavir. Acyclovir has no known therapeutic efficacy against CMV and is allowable as standard of care to prevent herpes simplex virus (HSV) (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Prophylactic therapy with CMV immunoglobulin or prophylactic antiviral CMV treatment EXCEPT letermovir prophylaxis (prior to day 100) (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Disease-based radiation therapy (not total body irradiation) (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Other investigational product(s) - concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibited (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Other medications that might interfere with the evaluation of the investigational product (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Patients with active autoimmune conditions requiring systemic immunosuppressive therapy within the previous 5 years.\n* RECIPIENTS: Patients considered by PI\u002Fconsenting physicians to have a complicated prior therapy or HCT regimen, or who have a low survival probability (e.g., refractory leukemia and\u002For undergoing 2nd HCT).\n* RECIPIENTS: Poor risk disease\u002Fdisease status including: Chronic myelogenous leukemia (CML) in blast crisis, acute myeloid leukemia (AML)\u002Facute lymphoblastic leukemia (ALL) beyond 2nd remission, multiple myeloma, and aplastic anemia.\n* RECIPIENTS: Females only: Pregnant or breastfeeding.\n* RECIPIENTS: Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.\n* RECIPIENTS: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics).",{"count":353,"type":22},46,[228],"This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cell transplantation (haploHCT) has advanced to become the predominant procedure for patients lacking a matched donor. Compared to matched related donor transplants, the rate of significant CMV infection is higher in patients undergoing a haploHCT. Significant CMV infection is associated with an increased risk of complications and death. Vaccination is the main preventative approach to limit complications and death in immunocompromised patients at high risk of post-stem cell transplant infections. CMV-MVA Triplex vaccine, is a CMV vaccine based on the attenuated poxvirus, modified vaccinia Ankara (MVA), developed to enhance CMV-specific immunity in both healthy stem cell transplant donors and stem cell transplant patients to prevent significant CMV infection post-stem cell transplant. Giving CMV-MVA triplex vaccine may be safe, tolerable and\u002For effective in enhancing cytomegalovirus (CMV)-specific immunity and preventing CMV viremia in patients undergoing a haploHCT.",[357,358,359,360,361,29,272,362,278,363,364,365],"Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Chronic Lymphocytic Leukemia","Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","Lymphoblastic Lymphoma","Myelofibrosis","Myeloproliferative Neoplasm","Non-Hodgkin Lymphoma",{"date":286,"type":34},{"date":368,"type":34},"2026-05-08",{"date":370,"type":22},"2029-05-30",{"name":372,"class":41},"City of Hope Medical Center",{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":23,"phases":382,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":387,"completionDateStruct":388,"leadSponsor":390,"locationsCount":64},"100649270","mindfulness-intervention-to-reduce-patient-reported-symptoms-in-patients-with-chronic-graft-versus-host-disease-100649270","NCT07733141","Mindfulness Intervention to Reduce Patient Reported Symptoms in Patients With Chronic Graft-Versus-Host Disease","Pilot Feasibility Study of Mindfulness-Based Intervention in Patients With Chronic Graft-Versus-Host Disease","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative\n* Willingness to participate in the study\n* Willingness to attend in-person or virtual group sessions\n* Ability to read and understand English (required for protocol therapy and planned survey)\n* Age: ≥ 18 years\n* Confirmed diagnosis of moderate\u002Fsevere chronic graft-versus-host disease by National Institute of Health (NIH) criteria\n* Karnofsky performance status ≥ 80\n\nExclusion Criteria:\n\n* Previous participation in four or more sessions of mindfulness-based cognitive therapy (MBCT)\u002F mindfulness-based stress reduction (MBSR)\n* An increase in anti-cGvHD medication (increased dosage or addition of a new medication) within 4 weeks prior to baseline evaluation\n* Severe psychiatric comorbidities (active psychosis, suicidal ideation) as determined by primary investigator (PI)\n* Concurrent malignancy, autoimmune disease, chronic infections, or other chronic inflammatory illness that might confound the results as determined by the PI\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)",{"count":381,"type":22},17,[25],"This clinical trial tests a mindfulness intervention, consisting of group sessions and an individual session, using mindfulness based stress reduction techniques, to reduce patient reported symptoms for patients with chronic graft versus host disease (cGVHD). In patients undergoing allogeneic stem cell transplant, sometimes the transplanted cells from a donor can attack the body's normal cells (called graft-versus-host disease). In cGVHD patients may encounter stiffness, itching, joint and muscle pain, oral cavity pain, itchy eyes, shortness of breath, depression, anxiety, and poor sleep resulting in a significant impact on patients' quality of life. Mindfulness interventions use meditation practices with elements of psychology to improve emotional regulation, resilience and acceptance based coping. This mindfulness based intervention may reduce patient reported symptoms in patients with cGVHD.",[118,29,55],"2026-07-23",{"date":306,"type":34},{"date":242,"type":22},{"date":389,"type":22},"2029-03-01",{"name":372,"class":41},{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":18,"minAge":398,"maxAge":399,"enrollmentInfo":400,"targetDuration":4,"studyType":23,"phases":401,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":408,"completionDateStruct":409,"leadSponsor":411,"locationsCount":64},"100648896","a-study-of-strengthening-teen-brain-resilience-using-music-during-cancer-treatment-100648896","NCT07729384","A Study of Strengthening Teen Brain Resilience Using Music During Cancer Treatment","Strengthening Teen Brain Resilience Using Music (STRUM) During Cancer Treatment: A Pilot Feasibility Trial","Inclusion Criteria:\n\n* Aged 12-17 years at the time of enrollment\n* Receiving initial radiation therapy (RT) for cancer treatment with curative intent at the Mayo Clinic Arizona\n* Able to provide assent\n* Able to read and write in English\n* Have access to an electronic device with videoconferencing capability\n\nExclusion Criteria:\n\n* Less than three-month prognosis\n* Past history of RT\n* Self-reported visual, hearing, or cognitive impairment impeding the ability to complete the STRUM intervention\n* Prior receipt of ukulele or guitar lessons\n* Actively receiving musical instrument lessons","12 Years","17 Years",{"count":94,"type":22},[25],"This clinical trial tests the feasibility and acceptability of the Strengthening Teen Brain Resilience Using Music (STRUM) intervention to improve radiation induced cognitive decline for adolescents undergoing radiation therapy for cancer treatment. Adolescents treated with radiation therapy for cancer often experience persistent cognitive deficits and reduced brain resilience or the ability to preserve cognitive and emotional functioning despite stressors. Musical instrument training has been shown to enhance memory, academic skills, and emotional well-being in youth. Although guitars are often the most preferred instrument, ukuleles offer greater accessibility due to their simplicity, affordability, and suitability for younger users. The STRUM intervention consists of virtual active music therapy ukulele lessons, which may be a feasible and acceptable way to improve radiation induced cognitive decline for adolescents undergoing radiation therapy for cancer treatment.",[404,405,29,55],"Childhood Hematopoietic and Lymphatic System Neoplasm","Childhood Malignant Solid Neoplasm","2026-07-22",{"date":339,"type":34},{"date":102,"type":22},{"date":410,"type":22},"2028-11-01",{"name":63,"class":41},{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":18,"minAge":418,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":426,"completionDateStruct":427,"leadSponsor":429,"locationsCount":64},"100611047","kinetic-analysis-of-immune-cells-in-blood-and-chronic-graft-versus-host-disease-affected-tissues-after-allogeneic-hematopoietic-cell-transplantation-100611047","NCT07235501","Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation","Inclusion Criteria:\n\n* \\* BOTH COHORTS:\n\n  * Documented written informed consent of the participant and\u002For parent\u002Fguardian.\n\n    * Assent from pediatric participants will be documented per institutional policies and practice.\n  * Patients who have received allogeneic hematopoietic cell transplant (HCT) regardless of donor type, condition regimen, or GVHD prophylaxis.\n  * Age: ≥ 18 years or ≥ 7 years if 30 kg and above\n  * Willingness to:\n\n    * Provide blood sample(s), stool, saliva, and buccal mucosa,\n    * If applicable: Permit medical record\u002F clinical laboratory result review\n\n      * COHORT 1:\n  * Patients who have received allogeneic hematopoietic cell transplant (HCT) regardless of donor type, condition regimen, or GVHD prophylaxis.\n\n    * COHORT 2:\n  * Patients diagnosed with cGVHD at any time-point after allogeneic HCT regardless of donor type, condition regimen, or GVHD prophylaxis.\n\nExclusion Criteria:\n\n* \\* Women of childbearing potential: Pregnant\u002Fnursing\n\n  * Individuals with impaired decision-making capacity\n  * An employee who is under the direct\u002F indirect supervision of the PI\u002F a co-investigator\u002F the study manager\n  * A direct study team member","7 Years",{"count":420,"type":22},75,"This study evaluates the factors that contribute to chronic graft-versus-host disease, which is a complication that can occur after allogeneic hematopoietic cell transplantation.",[423,29,55],"Graft Versus Host Disease","2026-07-20",{"date":406,"type":34},{"date":102,"type":22},{"date":428,"type":22},"2030-01-17",{"name":372,"class":41},{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":18,"minAge":437,"maxAge":438,"enrollmentInfo":439,"targetDuration":4,"studyType":23,"phases":441,"briefSummary":442,"conditions":443,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":448,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":64},"100517121","phase-2-cord-blood-transplant-cyclophosphamide-fludarabine-and-total-body-irradiation-in-treating-patients-with-high-risk-hematologic-diseases-100517121","NCT06013423","Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases","Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults and Pediatrics","Inclusion Criteria:\n\n* Patients aged 6 months to =\\\u003C 65 years at time of consent.\n* Acute myelogenous leukemia (AML):\n\n  * Complete first remission (CR1), complete second remission (CR2) or greater (CR2+), must have \\\u003C 5% marrow blasts at the time of transplant.\n  * Patients in morphologic remission with persistent cytogenetic, flow cytometric, or molecular aberrations are eligible.\n* Acute lymphoblastic leukemia (ALL):\n\n  * Complete first remission (CR1) at high risk for relapse such as any of the following:\n\n    * Presence of any high-risk cytogenetic abnormalities such as t(9;22), t(1;19), t(4;11) or other MLL rearrangements (11q23) or other high-risk molecular abnormality.\n    * Failure to achieve MRD- complete remission after induction therapy.\n    * Persistence or recurrence of minimal residual disease on therapy.\n    * Any patient unable to tolerate consolidation and\u002For maintenance chemotherapy as would have been deemed appropriate by the treating physician.\n    * Other high-risk features not defined above.\n  * Complete second remission (CR2) or greater (CR2+).\n\n    * Note: ALL with less than 5% blasts at time of transplant but persistent cytogenetic, flow cytometric or molecular aberrations are eligible.\n* Other acute leukemias: Acute leukemias of ambiguous lineage or mixed phenotype with less than 5% blasts. Leukemias in morphologic remission with persistent cytogenetic, flow cytometric or molecular aberrations are eligible.\n* Chronic Myeloid Leukemia (CML): Excluding refractory blast crisis. To be eligible in first chronic phase (CP1) patient must have failed or be intolerant to tyrosine kinase inhibitor therapy.\n* Myelodysplastic syndromes (MDS) and myeloproliferative disorders (MPD) other than myelofibrosis:\n\n  * MDS\u002FMPD overlap syndromes without myelofibrosis.\n  * MDS\u002F MPD patients must have less than 10% bone marrow myeloblasts and absolute neutrophil count (ANC) \\> 0.2 (growth factor supported if necessary) at transplant work-up.\n* Non-Hodgkin lymphoma (NHL) at high-risk of relapse or progression if not in remission:\n\n  * Eligible patients with aggressive histology (such as, but not limited to, diffuse large B-cell NHL, mantle cell NHL, and T-cell histology) in CR by PET\u002FCT imaging.\n  * Eligible patients with indolent B-cell NHL (such as, but not limited to, follicular, small cell or marginal zone NHL) will have 2nd or subsequent progression with PR or CR by PET\u002FCT imaging.\n* Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in morphologic remission.\n* Only for adult patients, to prevent graft rejection, patients who received only non-lymphodepleting agents for their malignancy (hypomethylating agents, venetoclax, hydroxyurea, TKIs etc.), or patients who received lymphodepleting chemotherapy \\> 3 months prior to scheduled admission, may receive fludarabine 25 mg\u002Fm\\^2 daily x 3 days for lymphodepletion 14-42 days (aiming for 2-4 weeks) at the discretion of the principal investigator (PI).\n* For patients \\> 18 years old, Karnofsky score ≥ 70%. For patients =\\\u003C 18 years old, Lansky score ≥ 50%.\n* Calculated creatinine clearance \\> 70 ml\u002Fmin.\n* Bilirubin \\\u003C 1.5 mg\u002FdL (unless benign congenital hyperbilirubinemia or hemolysis).\n* Alanine transaminase (ALT) \\\u003C 3 x upper limit of normal (ULN).\n* For patients \\> 18 years old, pulmonary function (spirometry and corrected diffusing capacity for carbon monoxide \\[DLCO\\]) \\> 60% predicted. For patients =\\\u003C 18 years old, or any patient unable to perform pulmonary function tests, O2 saturation \\> 92% on room air.\n* Left ventricular ejection fraction \\> 50%.\n* Albumin \\> 3.0 g\u002FdL.\n* For patients \\> 18 years old, Hematopoietic Cell Transplantation Comorbidity index (HCT-CI) =\\\u003C 5.\n* UCB units will be selected according to current umbilical cord blood graft selection algorithm. One or two UCB units may be used to achieve the required cell dose.\n* The UCB graft is matched at 4-6 HLA-A, B, DRB1 antigens with the recipient. This may include 0-2 antigen mismatches at the A or B or DRB1 loci. Unit selection based on cryopreserved nucleated cell dose and HLA-A, B, DRB1 using intermediate resolution A, B antigen and DRB1 allele typing.\n\nExclusion Criteria:\n\n* Diagnosis of myelofibrosis or other malignancy with moderate-severe bone marrow fibrosis.\n* Patients persistent with central nervous system (CNS) involvement in cerebrospinal fluid (CSF) or CNS imaging at time of screening0\n* Prior checkpoint inhibitors\u002F blockade in the last 12 months.\n* Two prior stem cell transplants of any kind.\n* One prior autologous stem cell transplant within the preceding 12 months.\n* Prior allogeneic transplantation.\n* Prior involved field radiation therapy that would preclude safe delivery of 400cGy total body irradiation (TBI) in the opinion of radiation oncology.\n* Active and uncontrolled infection at time of transplantation.\n* HIV infection.\n* Inadequate performance status\u002F organ function.\n* Pregnancy or breast feeding.\n* Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, long-term follow-up, and research tests.","6 Months","65 Years",{"count":440,"type":22},54,[139],"This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases. Giving chemotherapy, such as cyclophosphamide, fludarabine and thiotepa, and TBI before a donor cord blood transplant (CBT) helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after transplant may stop this from happening in patients with high-risk hematologic diseases.",[444,358,359,445,29,446,278,364,365,447],"Acute Leukemia of Ambiguous Lineage","Blastic Plasmacytoid Dendritic Cell Neoplasm","Mixed Phenotype Acute Leukemia","Chronic Myeloid Leukemia, BCR-ABL1 Positive",{"date":406,"type":34},{"date":450,"type":34},"2024-07-23",{"date":452,"type":22},"2032-10-31",{"name":40,"class":41},{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":461,"enrollmentInfo":462,"targetDuration":4,"studyType":23,"phases":463,"briefSummary":464,"conditions":465,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":64},"100644683","transcranial-direct-current-stimulation-for-the-treatment-of-chemotherapy-induced-peripheral-neuropathy-in-cancer-survivors-100644683","NCT07673614","Transcranial Direct Current Stimulation for the Treatment of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors","Improving Sensorimotor Function in CIPN: A Randomized, Sham Controlled, Double Blinded, Crossover Mechanistic Trial of Transcranial Direct Current to the Sensorimotor Cortex","Inclusion Criteria:\n\n* 18 to 85 years of age\n* Diagnosis of cancer, stages I-IV\n* Cancer survivor (not currently receiving chemotherapy, radiation, or immunotherapy)\n* Presence of CIPN defined as new, length-dependent numbness, tingling, and\u002For pain that developed with neurotoxic chemotherapy\n* CIPN20 score ≥ 20\n* Able to walk unassisted\n* Proficient in English\n\nExclusion Criteria:\n\n* Known brain metastases\n* Known neurological conditions aside from chemotherapy-induced peripheral neuropathy (CIPN)\n* History of brain or spinal surgery\n* Neuropathy other than CIPN\n* Significant hearing or vision deficits\n* Vestibulopathy\n* Currently receiving chemotherapy, radiation therapy, or immunotherapy\n* Contraindications to transcranial direct current stimulation (tDCS), including recent seizures\n* Presence of metallic objects in the head\n* Presence of specific implanted medical devices (e.g., deep brain stimulator, cochlear implant, vagus nerve stimulator, spinal cord stimulator, pacemakers, and intracardiac devices)\n* Active scalp dermatological conditions","85 Years",{"count":335,"type":22},[25],"This clinical trial tests how well a type of non-invasive brain stimulation called transcranial direct current stimulation (tDCS) works to treat chemotherapy induced peripheral neuropathy (CIPN) in cancer survivors. CIPN is numbness, tingling, pain, and movement problems that can develop after chemotherapy as a result of changes to the nerves. A non-invasive form of brain stimulation called tDCS, applied to the area of the brain involved in sensation and movement, can temporarily improve the ability to detect vibration and temperature, as well as balance and walking, which may improve sensation and reduce pain in cancer survivors with CIPN.",[466,29,55],"Chemotherapy-Induced Peripheral Neuropathy","2026-07-16",{"date":469,"type":34},"2026-07-17",{"date":471,"type":22},"2026-08-01",{"date":473,"type":22},"2028-02",{"name":106,"class":41},{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":482,"minAge":4,"maxAge":92,"enrollmentInfo":483,"targetDuration":4,"studyType":23,"phases":484,"briefSummary":486,"conditions":487,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":497},"100555582","phase-3-triptorelin-for-the-prevention-of-ovarian-damage-in-adolescents-and-young-adults-with-cancer-100555582","NCT06513962","Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer","Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults With Cancer","Inclusion Criteria:\n\n* \\\u003C 40 years of age at the time of enrollment\n* Patient must be a post-menarchal female and report that their initial menstrual period occurred \\> 6 months prior to enrollment. (Current menstrual status is not part of the inclusion criteria.)\n* Newly diagnosed with first cancer, exclusive of breast cancer.\n\n  * Note: Apart from breast carcinoma, other tumor types originating in the breast are permitted (e.g., sarcoma, lymphoma).\n* Planned treatment must include one or more of the following alkylating agents delivered with curative intent: cyclophosphamide, ifosfamide, procarbazine, chlorambucil, carmustine (BCNU), lomustine (CCNU), melphalan, thiotepa, busulfan, nitrogen mustard, or dacarbazine (DTIC).\n* Expected cumulative cyclophosphamide equivalent dose (CED):\n\n  * For patients \\\u003C 20 years of age at enrollment, the expected alkylator dose must be ≥ 4 g\u002Fm\\^2 cumulative CED calculated according to the equation and specified drugs listed. Dacarbazine is not an eligible drug in this age group.\n  * For patients ≥ 20 years of age and \\\u003C 35 years old at enrollment, any planned alkylator dose is permitted. Eligible patients must receive at least one of the alkylators listed below that contribute to CED. Dacarbazine is not an eligible drug in this age group.\n  * For patients ≥ 35 years of age at enrollment, any planned alkylator dose is permitted. Eligible patients must receive at least one of the alkylators listed that contribute to CED and\u002For dacarbazine, which IS an eligible drug in this age group.\n\nNote that CED includes all administration routes: intravenous (IV), oral (PO), IM.\n\n* The planned total duration of therapy with eligible alkylators is expected to be completed within one year after enrollment. Note: treatment plans with prolonged maintenance periods extending beyond one year are permitted so long as those maintenance treatments are not expected to contain eligible alkylators.\n* All patients and\u002For their parents or legal guardians must sign a written informed consent.\n* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met.\n\nExclusion Criteria:\n\n* Any planned radiation to the pelvis; or cranial radiation ≥ 30 gray (Gy) to the hypothalamus, inclusive of any total body irradiation (TBI).\n* Planned bilateral oophorectomy. Note: A participant's desire to pursue alternative fertility preservation procedures (i.e., embryo, oocyte, or ovarian tissue cryopreservation) will be allowed (and in fact encouraged).\n* Congenital syndromes associated with infertility and decreased ovarian reserve at baseline. For example: Turner's Syndrome, Fragile X premutation carriers, Down syndrome, etc.\n* Pre-existing seizure disorder, congenital long QT syndrome, pseudotumor cerebri; history of pulmonary embolism, venous thrombosis, or myocardial infarction. Note: Contact study chairs if questions arise about other pre-existing conditions.\n* Receipt of long acting (depot) GnRH agonists within 6 months before enrollment. In contrast, subcutaneous GnRH agonist used for oocyte retrieval is not an exclusion; oral and other hormonal contraceptive use is also not an exclusion. Note: Please see protocol for the concomitant therapy restrictions for patients during the study treatment period. See protocol for information about oral and other hormonal contractive use during the study treatment period.\n* Receipt of systemic chemotherapy (except for steroids and intrathecal chemotherapy) more than 7 days prior to study enrollment.\n* Any prior radiation to the pelvis; or cranial radiation ≥ 30 Gy to the hypothalamus, inclusive of any total body irradiation (TBI).\n* Patients who are pregnant are not eligible. A pregnancy test is required for female patients of childbearing potential.\n* Lactating females who plan to breastfeed their infants for the duration of triptorelin therapy (24 weeks per dose).\n* Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of triptorelin therapy (24 weeks per dose).","FEMALE",{"count":177,"type":22},[485],"PHASE3","This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovaries to slow down or pause normal activity. The triptorelin used in this study stays active in the body for 24 weeks or about 6 months after a dose is given. After triptorelin is cleared from the body, the ovaries resume normal activities. Adding triptorelin before the start of chemotherapy treatment may reduce the chances of damage to the ovaries.",[29,55],"2026-07-15",{"date":469,"type":34},{"date":491,"type":34},"2025-02-27",{"date":493,"type":22},"2029-10-30",{"name":495,"class":496},"Children's Oncology Group","NETWORK",205,{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":4,"eligibilityCriteria":504,"healthyVolunteers":12,"sex":18,"minAge":505,"maxAge":92,"enrollmentInfo":506,"targetDuration":4,"studyType":23,"phases":507,"briefSummary":508,"conditions":509,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":64},"100588432","solution-focused-brief-therapy-for-support-of-psychological-distress-in-adolescent-and-young-adult-cancer-survivors-100588432","NCT06941324","Solution-Focused Brief Therapy for Support of Psychological Distress in Adolescent and Young Adult Cancer Survivors","SFBT for AYA Cancer Survivors' Psychological Distress: Evaluating Solution-Focused Brief Therapy as a Strength-Based Psychotherapeutic Intervention for Psychological Distress in Adolescents and Young Adults With Cancer","Inclusion Criteria:\n\n* 15 - 39 years old\n* Diagnosed with cancer\n* Receiving active cancer care (6 weeks post initial diagnosis to control for emotional responses to normative stressors) or within 5 years of post-treatment survivorship\n* Experiencing psychological distress (i.e., a t-score \\>= 57 on the Brief Symptom Inventory - 18 items \\[BSI-18\\])\n* Fluent in English\n\nExclusion Criteria:\n\n* End-of-life care\n* \\> 5 years into the post-treatment survivorship\n* Major physical challenges (e.g., hearing loss, developmental delay)\n* Acute mental health conditions (e.g., active psychosis, suicide risk)\n* Receiving or newly initiated psychotherapy for psychological distress during the study period","15 Years",{"count":177,"type":22},[25],"This clinical trial evaluates the how well a virtually delivered solution-focused brief therapy (SFBT-C) works to decrease adolescent and young adult cancer survivors' psychological distress in comparison to enhanced treatment-as-usual care. Cancer and its treatment can have immediate and long-term impacts on adolescent and young adult cancer survivor's lives, including education and employment, financial stability, sexual health, and social, romantic, and family relationships. Consequently, many adolescent and young adult cancer survivors report psychological distress, often manifesting as depression and anxiety, and may benefit from psychotherapy to improve their engagement with medical treatment and overall quality of life. SFBT-C is a theory-driven and brief hope-based psychotherapy designed for the unique psychosocial needs facing adolescent and young adult cancer survivors. Undergoing SFBT-C may work better than treatment-as-usual care for the support of psychological distress in adolescent and young adult cancer survivors.",[29,55],"2026-07-14",{"date":467,"type":34},{"date":513,"type":34},"2025-06-23",{"date":515,"type":22},"2028-07-01",{"name":106,"class":41},{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":524,"targetDuration":4,"studyType":23,"phases":525,"briefSummary":526,"conditions":527,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":64},"100594906","phase-1-biomarker-guided-ruxolitinib-for-the-prevention-of-chronic-graft-versus-host-disease-after-allogeneic-hematopoietic-cell-transplantation-100594906","NCT07025538","Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation","Biomarker-Guided Feasibility\u002FEfficacy Trial of Ruxolitinib in Patients With High-Risk of Chronic Graft-Versus-Host Disease Development After Allogeneic Hematopoietic Cell Transplantation","Inclusion Criteria:\n\n* PRE-SCREENING: Documented informed consent of the participant and\u002For legally authorized representative\n\n  * Assent, when appropriate, will be obtained per institutional guidelines\n* PRE-SCREENING: Agreement to allow the use of archival tissue from diagnostic tumor biopsies\n\n  * If unavailable, exceptions may be granted with study principal investigator (PI) approval\n* PRE-SCREENING: Age: ≥ 18 years\n* PRE-SCREENING: Karnofsky performance status ≥ 80\n* PRE-SCREENING: Patients must have undergone allogeneic hematopoietic cell transplantation with peripheral blood stem cells as graft source. Note: Patients receiving manipulated graft are not included\n* PRE-SCREENING: Morphologic remission per day +30 bone marrow\n* PRE-SCREENING: Any conditioning regimen (myeloablative, reduce intensity\u002Fnon-myeloablative conditioning) is allowed\n* PRE-SCREENING: Any GVHD prophylaxis (tacrolimus-sirolimus, tacrolimus-methotrexate, or post-transplant cyclophosphamide) is allowed\n* PRE-SCREENING: Life expectancy of more than 6 months\n* PRE-SCREENING: Absolute neutrophil count (ANC) \\> 1000\u002Fmm\\^3 (to be performed between day +70 and +100 after HCT unless otherwise stated)\n* PRE-SCREENING: Hemoglobin ≥ 8.0 gm\u002FdL (to be performed between day +70 and +100 after HCT unless otherwise stated)\n* PRE-SCREENING: Platelets ≥ 50,000\u002Fmm\\^3 (to be performed between day +70 and +100 after HCT unless otherwise stated)\n\n  * Note: Patients with lower counts can enroll if infection cytomegalovirus (CMV)\u002Fhuman herpesvirus 6 (HHV6), etc. is being treated actively\n* PRE-SCREENING: Total bilirubin ≤ 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease) (to be performed between day +70 and +100 after HCT unless otherwise stated)\n* PRE-SCREENING: Aspartate aminotransferase (AST) =\\\u003C 3.0 x ULN (to be performed between day +70 and +100 after HCT unless otherwise stated)\n* PRE-SCREENING: Alanine aminotransferase (ALT) =\\\u003C 3.0 x ULN (to be performed between day +70 and +100 after HCT unless otherwise stated)\n* PRE-SCREENING: Glomerular filtration rate (GFR) ≥ 50 ml\u002Fmin (to be performed between day +70 and +100 after HCT unless otherwise stated)\n* PRE-SCREENING: Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (to be performed between day +70 and +100 after HCT unless otherwise stated)\n\n  * If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* PRE-SCREENING: Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of protocol therapy\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only)\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH MODERATE TO HIGH-RISK cGVHD (TREATMENT ARM): Documented informed consent of the participant and\u002For legally authorized representative\n\n  * Assent, when appropriate, will be obtained per institutional guidelines\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH MODERATE TO HIGH-RISK cGVHD (TREATMENT ARM): Elevated serum\u002Fplasma levels of ST2, CXCL9, MMP-3, and OPN as indicated by moderate or severe risk of chronic GVHD in the test results\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH MODERATE TO HIGH-RISK cGVHD (TREATMENT ARM): No use of ruxolitinib or other Jak inhibitors in the past 14 days\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH MODERATE TO HIGH-RISK cGVHD (TREATMENT ARM): Morphologic remission per day +100 bone marrow\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH MODERATE TO HIGH-RISK cGVHD (TREATMENT ARM): Adequate hematopoietic recovery (hemoglobin \\[Hgb\\] ≥ 8 g\u002FdL, platelets \\[PLT\\] ≥ 50K\u002F mm\\^3)\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH MODERATE TO HIGH-RISK cGVHD (TREATMENT ARM): Negative serum or urine pregnancy test (female participants with childbearing potential only)\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH MODERATE TO HIGH-RISK cGVHD (TREATMENT ARM): Absence of active infection not responding to antibiotics\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH MODERATE TO HIGH-RISK cGVHD (TREATMENT ARM): Absence of progressive acute GVHD. Note: prednisone administration (flat dose of \\\u003C 0.25 mg\u002Fkg) is allowed. Patients receiving any other medication to control active\u002Fprogressive GVHD will be excluded\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH MODERATE TO HIGH-RISK cGVHD (TREATMENT ARM): Absence of any clinically significant uncontrolled sickness\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH LOW-RISK cGVHD (CONTROL ARM): Documented informed consent of the participant and\u002For legally authorized representative\n\n  * Assent, when appropriate, will be obtained per institutional guidelines\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH LOW-RISK cGVHD (CONTROL ARM): Low serum\u002Fplasma levels of ST2, CXCL9, MMP-3, and OPN as indicated by low risk of chronic GVHD in the test results\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH LOW-RISK cGVHD (CONTROL ARM): No use of ruxolitinib or other Jak inhibitors in the past 14 days\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH LOW-RISK cGVHD (CONTROL ARM): Morphologic remission per day +100 bone marrow\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH LOW-RISK cGVHD (CONTROL ARM): Adequate hematopoietic recovery (Hgb ≥ 8 g\u002FdL, PLT ≥ 50K\u002F mm\\^3)\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH LOW-RISK cGVHD (CONTROL ARM): Negative serum or urine pregnancy test (female participants with childbearing potential only)\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH LOW-RISK cGVHD (CONTROL ARM): Absence of active infection not responding to antibiotics\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH LOW-RISK cGVHD (CONTROL ARM): Absence of progressive acute GVHD. Note: prednisone administration (flat dose of \\\u003C 0.25 mg\u002Fkg) is allowed. Patients receiving any other medication to control active\u002Fprogressive GVHD will be excluded\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH LOW-RISK cGVHD (CONTROL ARM): Absence of any clinically significant uncontrolled sickness\n\nExclusion Criteria:\n\n* PRE-SCREENING: Prior chemotherapy \\\u003C 14 days prior to study biospecimen collection on day +100 post-HCT\n* PRE-SCREENING: Previous use of ruxolitinib or other JAK-inhibitors is allowed but administration should be stopped for at least 14 days prior to enrollment. Note: Previous use of Jak inhibitors before enrollment (including the pre-HCT period) should be recorded\n* PRE-SCREENING: History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent\n* PRE-SCREENING: Active\u002Fprogressive acute GVHD at the time of screening. Prednisone administration (flat dose of \\\u003C 0.25 mg\u002Fkg) is allowed. Patients receiving any other medication to control active\u002Fprogressive GVHD will be excluded\n* PRE-SCREENING: Patients with history of major adverse cardiovascular event (MACE)\u002Fother thrombosis (myocardial infarction \\[MI\\]\u002Fstroke and pulmonary embolism \\[PE\\]\u002Fdeep vein thrombosis \\[DVT\\]) in the past 6 months\n* PRE-SCREENING: Patients with a history of tuberculosis\n* PRE-SCREENING: Clinically significant uncontrolled illness\n* PRE-SCREENING: Active infection not responding to antibiotics\n* PRE-SCREENING: Other active malignancy. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* PRE-SCREENING: Females only: Pregnant or breastfeeding\n* PRE-SCREENING: Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* PRE-SCREENING: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)",{"count":226,"type":22},[228],"This phase I trial studies how well biomarker-guided ruxolitinib works for the prevention of chronic graft versus host disease (GVHD) in patients that have undergone allogeneic hematopoietic cell transplant (HCT). Allogeneic HCT is the most effective therapy for patients with high-risk blood and bone marrow malignancies. GVHD is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Symptoms include jaundice, skin rash or blisters, a dry mouth, or dry eyes. In chronic GVHD (cGVHD), symptoms occur more than three months after transplantation. Despite significant advances in how allogeneic HCTs are conducted, cGHVD remains a major limitation to the long-term success of the transplant and can impact patients' quality of life post-transplant. Checking GVHD biomarkers in patients' blood after allogeneic HCT may help doctors predict how likely the patient is to develop cGVHD. This information can be used to help guide patients with high levels to receive cGVHD preventative therapy with ruxolitinib. Ruxolitinib works by blocking some of the enzymes that are needed for the development of cGVHD, which may be an effective way to prevent cGVHD in patients with high levels of GVHD biomarkers.",[29],"2026-07-10",{"date":530,"type":34},"2026-07-13",{"date":532,"type":34},"2026-04-29",{"date":534,"type":22},"2028-06-22",{"name":372,"class":41},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":542,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":544,"conditions":545,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":552,"locationsCount":553},"100531462","evaluation-of-a-novel-auto-segmentation-algorithm-for-normal-structure-delineation-in-radiation-treatment-planning-100531462","NCT06200116","Evaluation of a Novel Auto Segmentation Algorithm for Normal Structure Delineation in Radiation Treatment Planning","Inclusion Criteria:\n\n* Employment at Mayo Clinic Arizona, Florida, or Rochester (which includes Regional Practice sites located at Mayo Clinic Health System locations) as train clinical staff that participate in normal tissue segmentation\n\nExclusion Criteria:\n\n* Inability to complete study surveys",{"count":543,"type":22},200,"This study measures the utility of a novel artificial intelligence (AI) algorithm for performing auto-segmentation of computed tomography (CT) scans for radiation therapy planning.",[55,29],"2026-07-06",{"date":548,"type":34},"2026-07-08",{"date":550,"type":34},"2024-12-02",{"date":189,"type":22},{"name":63,"class":41},7,{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":558,"acronym":4,"eligibilityCriteria":559,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":562,"conditions":563,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":4},"100646490","wearable-data-for-personalized-prognostication-in-cancer-a-registry-protocol-100646490","NCT07691008","Wearable Data for Personalized Prognostication in Cancer: A Registry Protocol","Inclusion Criteria:\n\n* Age: ≥ 18 years\n* Has Apple Health app on personal device with valid iOS operating software (i.e., iOS 15.0 or higher)\n* Has a registered MyChart\u002FMyCityofHope account (or be willing to register for one) and the app downloaded onto the personal device that also contains the Apple Health app with their data\n* Ability to read and understand English to review MyChart\u002FMyCityofHope on-screen instructions to sync and share Apple Health data\n* Meets one of the below criteria:\n* Any patient at City of Hope who had and\u002For has a cancer-related visit (e.g., high risk, newly diagnosed, receiving treatment, active follow-up, survivorship etc.)\n* City of Hope employee\n\nExclusion Criteria:\n\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)\n* City of Hope employees listed on the study roster or who manage employees listed on the study roster",{"count":561,"type":22},1200,"This study receives physiological and lifestyle-related data from mobile phones to create an institutional database.",[564,55,565,29],"Hematopoietic Neoplasm","Lymphatic System Neoplasm","2026-07-02",{"date":548,"type":34},{"date":569,"type":22},"2026-12-01",{"date":571,"type":22},"2034-12-01",{"name":372,"class":41}]